



JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,
Sector-18, Gurugram -122015, Haryana (India)

Ph.: +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com

CIN. : L74899DL1978PLC009181



September 24, 2025

The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Department of Corporate Services- Listing National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
---	--

Subject: Proceedings of the 46th Annual General Meeting ('AGM') of the Company and disclosure under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') read with Para A of Part A of Schedule III of the Listing Regulations, please find enclosed herewith summary of the proceedings of the 46th AGM of the Company held through Video Conference/ Other Audio Visual Means (VC/OAVM) on Wednesday, September 24, 2025 (commenced at 3:30 p.m. and concluded at 4:23 p.m.).

The detailed results of e-Voting (both for remote e-Voting and Voting at AGM) along with Scrutinizer's Report shall be intimated separately.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For Jagsonpal Pharmaceuticals Limited

**PRATHA
M RAWAL**

Digitally signed by
PRATHAM RAWAL
Date: 2025.09.24
17:35:51 +05'30'

Pratham Rawal

Company Secretary & Compliance Officer

Encl.: As above

Regd. Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India)
Mumbai Office: 13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070



JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India)

Ph.: +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com

CIN. : L74899DL1978PLC009181



Summary of the Proceedings of the 46th Annual General Meeting of Jagsonpal Pharmaceuticals Limited through Video Conferencing ('VC')/Other Audio Video Means ('OVAM')

The 46th Annual General Meeting ('AGM') of the members of Jagsonpal Pharmaceuticals Limited ('the Company') was held on Wednesday, September 24, 2025 at 03:30 p.m. (IST) through Video Conferencing/Other Audio Visual Means ('VC/OAVM') in accordance with the applicable provisions of Companies Act, 2013 read with the Rules, Circulars issued thereunder and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

Mr. Harsha Raghavan, Non-Executive Chairman of the Company chaired to conduct the proceedings of the AGM.

The Requisite quorum being present, the Chairman called the meeting to be in order and welcomed all the members. The Notice of AGM and Auditor's Report were taken as read.

The Chairman and Managing Director addressed the members present at the meeting and briefed the members about Company's operations, achievements and future outlook of the Company.

Mr. Pratham Rawal, Company Secretary apprised the members that in Compliance with provision of Section 108 of the Companies Act, 2013, Rule 20 of the Companies (Management and Administration) Rules 2014, as amended and applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company had provided members the facility to cast vote electronically through remote e-Voting (which started at 09.00 A.M. on Saturday, September 20, 2025, and concluded at 05:00 P.M. on Tuesday, September 23, 2025 electronically on all the resolutions as set forth in the AGM Notice. Further, the members who were present at the meeting and have not cast their vote by remote e-voting were allowed to cast their votes at the AGM. Following items of business were transacted at the meeting:

Item No.	Resolution description	Type of resolution
Ordinary Business		
1	Adoption of Audited Financial Statements for the Financial Year ended March 31, 2025	Ordinary
2	Declaration of Dividend for the Financial Year ended March 31, 2025	Ordinary
3	To appoint a director in place of Mr. Manish Gupta, Managing Director of the company, (DIN 06805265) who retires by rotation and being eligible, offers himself, for reappointment.	Ordinary
Special Business		
4	Ratification of remuneration payable to M/s. Kirit Mehta & Co. Cost Accountants, Cost Auditors of the Company for the Financial Year ending March 31, 2026	Ordinary
5	Revision in remuneration payable to Mr. Manish Gupta, Managing Director of the company	Special

Regd. Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India)

Mumbai Office: 13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070



JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India)

Ph.: +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com

CIN. : L74899DL1978PLC009181



A CSR Initiative

6	Appointment of Secretarial Auditor	Ordinary
---	------------------------------------	----------

The members were invited to make their comments and raise queries. The queries raised with respect to the Operations, performance and future prospects of the Company were responded to the members present.

Further, the members were informed that Mr. Ayush Khandelwal, M/s Ayush Khandelwal & Associates., Company Secretaries was appointed as Scrutinizer to scrutinize the remote e-voting and evoting at AGM and the voting results on resolutions will be announced on receipt of Consolidated Scrutiniser's Report within 2 working days from the conclusion of the meeting and simultaneously be disseminated to the stock exchanges and also be placed on the website of the Company and National Securities Depository Limited (NSDL).

The Chairman then thanked the members present at the meeting and declared the meeting closed at 4:23 P.M.

You are requested to take the same as compliance under Regulation 30 of the Listing Regulations. Voting Results, in the format prescribed pursuant to Regulation 44(3) of the Listing Regulations, shall be submitted in due course.

The Chairman concluded the meeting with a vote of thanks.

Yours faithfully,

For Jagsonpal Pharmaceuticals Limited

**PRATHAM
RAWAL**

Digitally signed by
PRATHAM RAWAL
Date: 2025.09.24
17:37:09 +05'30'

Pratham Rawal

Company Secretary & Compliance Officer

Regd. Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India)

Mumbai Office: 13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070